BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 119.1 CNY | +1.32% |
|
+0.78% | -4.33% |
| Apr. 22 | Beijing Balance Medical Technology Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Feb. 28 | Balance Medical Technology's Profit Jumps 21% in 2023 | MT |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 88.25 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -4.33% | 2.22B | - | - | |
| +10.41% | 125B | A- | ||
| -7.14% | 10.97B | A- | ||
| +2.70% | 8.99B | C | ||
| +35.49% | 5.38B | B+ | ||
| -15.96% | 4.86B | C | ||
| +8.15% | 3.43B | C- | ||
| -9.68% | 2.78B | B- | ||
| -0.90% | 2.21B | - | ||
| -21.53% | 1.82B | - | C- |
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
-
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- 688198 Stock
- Ratings Beijing Balance Medical Technology Co.,Ltd.